| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depressive Disorder, Major | 71 | 2025 | 254 | 12.070 |
Why?
|
| Antipsychotic Agents | 44 | 2025 | 302 | 6.370 |
Why?
|
| Psychotic Disorders | 38 | 2025 | 160 | 6.200 |
Why?
|
| Antidepressive Agents | 42 | 2025 | 225 | 5.210 |
Why?
|
| Psychopharmacology | 6 | 2024 | 13 | 4.750 |
Why?
|
| Sertraline | 35 | 2025 | 58 | 3.220 |
Why?
|
| Depressive Disorder | 46 | 2015 | 285 | 3.150 |
Why?
|
| Bipolar Disorder | 18 | 2024 | 246 | 3.050 |
Why?
|
| Benzodiazepines | 30 | 2024 | 100 | 2.600 |
Why?
|
| Periodicals as Topic | 4 | 2024 | 174 | 2.560 |
Why?
|
| Psychotropic Drugs | 4 | 2022 | 81 | 2.260 |
Why?
|
| Affective Disorders, Psychotic | 16 | 2019 | 17 | 2.070 |
Why?
|
| Depression | 27 | 2024 | 883 | 1.990 |
Why?
|
| Psychiatric Status Rating Scales | 40 | 2024 | 393 | 1.850 |
Why?
|
| Drug Therapy, Combination | 34 | 2025 | 463 | 1.780 |
Why?
|
| Humans | 186 | 2025 | 62678 | 1.450 |
Why?
|
| Suicide | 6 | 2021 | 126 | 1.400 |
Why?
|
| Editorial Policies | 2 | 2021 | 55 | 1.380 |
Why?
|
| Double-Blind Method | 38 | 2025 | 739 | 1.190 |
Why?
|
| Pharmacogenetics | 5 | 2020 | 27 | 1.100 |
Why?
|
| Mental Disorders | 6 | 2022 | 756 | 1.100 |
Why?
|
| Adult | 104 | 2025 | 16625 | 1.090 |
Why?
|
| Hydrocortisone | 22 | 2016 | 192 | 1.090 |
Why?
|
| Pharmacogenomic Testing | 4 | 2020 | 7 | 1.080 |
Why?
|
| Fluoxetine | 15 | 2014 | 44 | 1.050 |
Why?
|
| Suicidal Ideation | 5 | 2024 | 116 | 1.010 |
Why?
|
| Polypharmacy | 2 | 2021 | 61 | 1.000 |
Why?
|
| Electroconvulsive Therapy | 8 | 2024 | 15 | 0.970 |
Why?
|
| Cyclohexanols | 9 | 2014 | 17 | 0.930 |
Why?
|
| Depression, Postpartum | 6 | 2018 | 132 | 0.930 |
Why?
|
| Middle Aged | 83 | 2025 | 17363 | 0.910 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2024 | 11 | 0.900 |
Why?
|
| Suicide, Attempted | 5 | 2017 | 106 | 0.890 |
Why?
|
| Antidepressive Agents, Second-Generation | 9 | 2016 | 30 | 0.880 |
Why?
|
| Direct-to-Consumer Advertising | 1 | 2024 | 2 | 0.880 |
Why?
|
| Treatment Outcome | 41 | 2025 | 5590 | 0.880 |
Why?
|
| Female | 114 | 2025 | 32488 | 0.860 |
Why?
|
| Male | 106 | 2025 | 29483 | 0.840 |
Why?
|
| Agnosia | 1 | 2023 | 4 | 0.840 |
Why?
|
| Anti-Anxiety Agents | 3 | 2012 | 31 | 0.750 |
Why?
|
| Drug Approval | 1 | 2021 | 26 | 0.720 |
Why?
|
| Delusions | 10 | 2022 | 15 | 0.720 |
Why?
|
| Cognitive Dysfunction | 5 | 2024 | 330 | 0.670 |
Why?
|
| Citalopram | 5 | 2020 | 21 | 0.660 |
Why?
|
| Anxiety Disorders | 8 | 2015 | 192 | 0.640 |
Why?
|
| Aged | 53 | 2025 | 14254 | 0.600 |
Why?
|
| White Matter | 4 | 2023 | 123 | 0.600 |
Why?
|
| Cholecalciferol | 1 | 2017 | 27 | 0.550 |
Why?
|
| Dexamethasone | 19 | 1996 | 205 | 0.550 |
Why?
|
| Vitamin D Deficiency | 1 | 2017 | 42 | 0.540 |
Why?
|
| Clinical Competence | 1 | 2022 | 713 | 0.530 |
Why?
|
| Adolescent | 29 | 2025 | 6172 | 0.520 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 718 | 0.500 |
Why?
|
| Cognition | 4 | 2020 | 481 | 0.480 |
Why?
|
| Drug Labeling | 2 | 2025 | 23 | 0.470 |
Why?
|
| Clozapine | 2 | 2025 | 33 | 0.470 |
Why?
|
| Young Adult | 20 | 2025 | 4633 | 0.470 |
Why?
|
| Dietary Supplements | 1 | 2017 | 232 | 0.470 |
Why?
|
| Brain | 8 | 2024 | 1550 | 0.450 |
Why?
|
| Comorbidity | 8 | 2018 | 1118 | 0.440 |
Why?
|
| Severity of Illness Index | 15 | 2015 | 1541 | 0.430 |
Why?
|
| Apathy | 1 | 2013 | 9 | 0.430 |
Why?
|
| Sexual Dysfunction, Physiological | 3 | 2013 | 27 | 0.420 |
Why?
|
| Memantine | 1 | 2013 | 23 | 0.420 |
Why?
|
| Motivation | 2 | 2013 | 283 | 0.420 |
Why?
|
| Remission Induction | 8 | 2025 | 147 | 0.410 |
Why?
|
| Piperazines | 2 | 2012 | 76 | 0.410 |
Why?
|
| Sulfides | 1 | 2012 | 22 | 0.400 |
Why?
|
| Nursing Homes | 7 | 2024 | 671 | 0.390 |
Why?
|
| Perimenopause | 1 | 2012 | 31 | 0.390 |
Why?
|
| Ovariectomy | 1 | 2012 | 101 | 0.380 |
Why?
|
| Hysterectomy | 1 | 2012 | 67 | 0.370 |
Why?
|
| Secondary Prevention | 12 | 2021 | 163 | 0.370 |
Why?
|
| Stress, Psychological | 1 | 2016 | 469 | 0.370 |
Why?
|
| Sexual Dysfunctions, Psychological | 3 | 2008 | 13 | 0.360 |
Why?
|
| Neuropsychological Tests | 8 | 2023 | 389 | 0.360 |
Why?
|
| Postmenopause | 1 | 2012 | 236 | 0.350 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2023 | 729 | 0.340 |
Why?
|
| Aged, 80 and over | 16 | 2025 | 5406 | 0.330 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 8 | 2018 | 120 | 0.330 |
Why?
|
| Affect | 5 | 2017 | 125 | 0.330 |
Why?
|
| Recurrence | 6 | 2024 | 634 | 0.330 |
Why?
|
| Health Status | 2 | 2012 | 433 | 0.330 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 4 | 2015 | 47 | 0.320 |
Why?
|
| Antimanic Agents | 2 | 2024 | 31 | 0.320 |
Why?
|
| Cerebral Cortex | 4 | 2020 | 256 | 0.320 |
Why?
|
| Biomarkers | 1 | 2015 | 1385 | 0.310 |
Why?
|
| Tachyphylaxis | 1 | 2009 | 3 | 0.310 |
Why?
|
| Gyrus Cinguli | 3 | 2018 | 57 | 0.310 |
Why?
|
| Pharmacovigilance | 2 | 2025 | 13 | 0.300 |
Why?
|
| Connectome | 2 | 2018 | 33 | 0.290 |
Why?
|
| Ambulatory Care Facilities | 1 | 2008 | 105 | 0.290 |
Why?
|
| Ambulatory Care | 2 | 2008 | 311 | 0.280 |
Why?
|
| Aging | 2 | 2017 | 740 | 0.280 |
Why?
|
| Diagnostic Errors | 1 | 2008 | 98 | 0.280 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2018 | 75 | 0.270 |
Why?
|
| Drug Substitution | 2 | 2024 | 42 | 0.270 |
Why?
|
| Drug Interactions | 4 | 2021 | 127 | 0.270 |
Why?
|
| Predictive Value of Tests | 4 | 2024 | 1077 | 0.260 |
Why?
|
| Venlafaxine Hydrochloride | 9 | 2014 | 15 | 0.260 |
Why?
|
| Academic Medical Centers | 1 | 2008 | 317 | 0.260 |
Why?
|
| Age Factors | 16 | 2019 | 1554 | 0.260 |
Why?
|
| Quality of Life | 5 | 2019 | 1221 | 0.250 |
Why?
|
| Psychometrics | 8 | 2015 | 377 | 0.250 |
Why?
|
| Mifepristone | 4 | 2006 | 19 | 0.240 |
Why?
|
| United States | 14 | 2025 | 7719 | 0.230 |
Why?
|
| Book Reviews as Topic | 1 | 2004 | 2 | 0.230 |
Why?
|
| Reproducibility of Results | 5 | 2020 | 1638 | 0.230 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2024 | 13 | 0.230 |
Why?
|
| Prevalence | 8 | 2020 | 1348 | 0.230 |
Why?
|
| Scientific Misconduct | 1 | 2004 | 12 | 0.230 |
Why?
|
| Disclosure | 1 | 2004 | 54 | 0.220 |
Why?
|
| Conflict of Interest | 1 | 2004 | 37 | 0.220 |
Why?
|
| Cytochrome P-450 CYP2C19 | 2 | 2021 | 8 | 0.220 |
Why?
|
| Frailty | 2 | 2024 | 130 | 0.220 |
Why?
|
| Michigan | 1 | 2024 | 43 | 0.220 |
Why?
|
| Risk Factors | 9 | 2021 | 5302 | 0.220 |
Why?
|
| Delirium | 2 | 1995 | 56 | 0.210 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2022 | 708 | 0.210 |
Why?
|
| Creatine | 2 | 2023 | 24 | 0.210 |
Why?
|
| Triazolam | 2 | 1993 | 4 | 0.210 |
Why?
|
| Dopamine | 10 | 1992 | 105 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2024 | 2147 | 0.200 |
Why?
|
| Analysis of Variance | 6 | 2008 | 608 | 0.200 |
Why?
|
| Schizophrenia | 4 | 2021 | 267 | 0.200 |
Why?
|
| Homes for the Aged | 1 | 2024 | 157 | 0.200 |
Why?
|
| Cost of Illness | 2 | 2025 | 161 | 0.200 |
Why?
|
| Catecholamines | 4 | 1987 | 31 | 0.200 |
Why?
|
| Anxiety | 2 | 2017 | 421 | 0.190 |
Why?
|
| Placebos | 7 | 2018 | 71 | 0.190 |
Why?
|
| Massachusetts | 2 | 2024 | 2061 | 0.190 |
Why?
|
| Receptors, GABA-A | 2 | 2019 | 25 | 0.190 |
Why?
|
| Perphenazine | 3 | 2003 | 5 | 0.190 |
Why?
|
| Antidepressive Agents, Tricyclic | 5 | 2003 | 19 | 0.190 |
Why?
|
| Cognition Disorders | 3 | 2015 | 220 | 0.190 |
Why?
|
| Saliva | 2 | 2016 | 103 | 0.190 |
Why?
|
| Genomics | 2 | 2023 | 357 | 0.180 |
Why?
|
| Surveys and Questionnaires | 5 | 2016 | 2648 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 163 | 0.180 |
Why?
|
| Pregnanolone | 3 | 2018 | 13 | 0.170 |
Why?
|
| Longitudinal Studies | 5 | 2024 | 1247 | 0.170 |
Why?
|
| Drug Prescriptions | 1 | 2022 | 168 | 0.170 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2020 | 7 | 0.170 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2020 | 12 | 0.170 |
Why?
|
| Alprazolam | 1 | 2000 | 4 | 0.170 |
Why?
|
| Clonazepam | 1 | 2000 | 3 | 0.170 |
Why?
|
| Drug Administration Schedule | 6 | 2011 | 299 | 0.170 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2000 | 17 | 0.170 |
Why?
|
| Behavioral Symptoms | 1 | 2000 | 16 | 0.170 |
Why?
|
| Pregnanes | 1 | 2019 | 1 | 0.160 |
Why?
|
| GABA Modulators | 1 | 2019 | 2 | 0.160 |
Why?
|
| Delayed-Action Preparations | 7 | 2014 | 115 | 0.160 |
Why?
|
| Drug Monitoring | 3 | 2017 | 118 | 0.160 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 2540 | 0.160 |
Why?
|
| Pirenzepine | 1 | 1999 | 5 | 0.160 |
Why?
|
| Hypothalamo-Hypophyseal System | 4 | 1996 | 88 | 0.150 |
Why?
|
| Pituitary-Adrenal System | 3 | 1996 | 60 | 0.150 |
Why?
|
| Pyrazoles | 1 | 2019 | 78 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2011 | 862 | 0.150 |
Why?
|
| Factor Analysis, Statistical | 2 | 2022 | 98 | 0.150 |
Why?
|
| Rest | 1 | 2018 | 44 | 0.150 |
Why?
|
| Patient Dropouts | 2 | 2024 | 49 | 0.150 |
Why?
|
| Sex Factors | 6 | 2019 | 973 | 0.150 |
Why?
|
| Placebo Effect | 3 | 2022 | 10 | 0.150 |
Why?
|
| Time Factors | 7 | 2013 | 3742 | 0.150 |
Why?
|
| Glucocorticoids | 4 | 2003 | 188 | 0.150 |
Why?
|
| Behavior | 2 | 2001 | 36 | 0.150 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 1992 | 122 | 0.150 |
Why?
|
| Pregnancy | 6 | 2018 | 2316 | 0.140 |
Why?
|
| Research Design | 5 | 2019 | 572 | 0.140 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 1 | 2017 | 5 | 0.140 |
Why?
|
| Norepinephrine | 5 | 1991 | 103 | 0.140 |
Why?
|
| Weight Gain | 2 | 2008 | 170 | 0.130 |
Why?
|
| Deep Brain Stimulation | 1 | 2017 | 66 | 0.130 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2013 | 87 | 0.130 |
Why?
|
| Women's Health | 2 | 2012 | 369 | 0.130 |
Why?
|
| Body Weight | 2 | 2018 | 377 | 0.130 |
Why?
|
| Methoxyhydroxyphenylglycol | 3 | 1991 | 9 | 0.130 |
Why?
|
| Steroids | 1 | 2016 | 54 | 0.130 |
Why?
|
| Diagnosis, Differential | 9 | 2012 | 964 | 0.130 |
Why?
|
| Benztropine | 1 | 1995 | 2 | 0.130 |
Why?
|
| Prospective Studies | 4 | 2017 | 3258 | 0.120 |
Why?
|
| Bipolar and Related Disorders | 1 | 2015 | 1 | 0.120 |
Why?
|
| Body Mass Index | 3 | 2014 | 864 | 0.120 |
Why?
|
| Social Adjustment | 2 | 2010 | 35 | 0.120 |
Why?
|
| Lithium | 3 | 2003 | 21 | 0.120 |
Why?
|
| Cerebrovascular Disorders | 1 | 2015 | 81 | 0.120 |
Why?
|
| Awareness | 1 | 2015 | 75 | 0.110 |
Why?
|
| United States Food and Drug Administration | 2 | 2025 | 90 | 0.110 |
Why?
|
| Hormone Antagonists | 2 | 2005 | 12 | 0.110 |
Why?
|
| Psychiatry | 2 | 2014 | 118 | 0.110 |
Why?
|
| Serotonin | 2 | 1992 | 60 | 0.110 |
Why?
|
| Research Support as Topic | 1 | 2014 | 40 | 0.110 |
Why?
|
| International Classification of Diseases | 2 | 2012 | 137 | 0.110 |
Why?
|
| Retrospective Studies | 8 | 2021 | 6535 | 0.110 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2014 | 9 | 0.110 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2015 | 146 | 0.110 |
Why?
|
| Proportional Hazards Models | 3 | 2025 | 726 | 0.110 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2013 | 19 | 0.110 |
Why?
|
| Brief Psychiatric Rating Scale | 3 | 2013 | 13 | 0.110 |
Why?
|
| Research Personnel | 1 | 2014 | 94 | 0.110 |
Why?
|
| Mood Disorders | 2 | 2012 | 72 | 0.110 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2013 | 10 | 0.110 |
Why?
|
| Drug Synergism | 1 | 2013 | 142 | 0.100 |
Why?
|
| Pregnenolone | 1 | 2013 | 4 | 0.100 |
Why?
|
| Temazepam | 1 | 1993 | 1 | 0.100 |
Why?
|
| Disease Progression | 3 | 2012 | 1159 | 0.100 |
Why?
|
| Energy Intake | 1 | 2014 | 171 | 0.100 |
Why?
|
| Amnesia | 1 | 1992 | 9 | 0.100 |
Why?
|
| Research | 1 | 2014 | 192 | 0.100 |
Why?
|
| Frail Elderly | 2 | 2024 | 109 | 0.100 |
Why?
|
| Personality Inventory | 4 | 2015 | 56 | 0.100 |
Why?
|
| Epilepsy | 1 | 2014 | 110 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 1997 | 585 | 0.100 |
Why?
|
| Aminoglutethimide | 1 | 1992 | 1 | 0.100 |
Why?
|
| Metyrapone | 1 | 1992 | 1 | 0.100 |
Why?
|
| Ketoconazole | 1 | 1992 | 8 | 0.100 |
Why?
|
| Nerve Net | 1 | 2013 | 97 | 0.100 |
Why?
|
| Premenopause | 1 | 2012 | 59 | 0.100 |
Why?
|
| Akathisia, Drug-Induced | 1 | 1991 | 5 | 0.100 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2012 | 80 | 0.090 |
Why?
|
| Feeding Behavior | 1 | 2014 | 259 | 0.090 |
Why?
|
| Accidental Falls | 1 | 2013 | 128 | 0.090 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 214 | 0.090 |
Why?
|
| Tranylcypromine | 1 | 1991 | 2 | 0.090 |
Why?
|
| Hospitalization | 6 | 2020 | 1344 | 0.090 |
Why?
|
| Premenstrual Syndrome | 1 | 2012 | 99 | 0.090 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 2445 | 0.090 |
Why?
|
| Choline | 2 | 2023 | 21 | 0.090 |
Why?
|
| Anisotropy | 2 | 2023 | 60 | 0.090 |
Why?
|
| Menopause | 1 | 2014 | 257 | 0.090 |
Why?
|
| Logistic Models | 4 | 2017 | 1273 | 0.090 |
Why?
|
| Heart Rate | 2 | 1991 | 319 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2018 | 1110 | 0.080 |
Why?
|
| Statistics as Topic | 2 | 2010 | 148 | 0.080 |
Why?
|
| Prognosis | 5 | 2015 | 1724 | 0.080 |
Why?
|
| Treatment Failure | 3 | 2020 | 198 | 0.080 |
Why?
|
| Blood Pressure | 2 | 1991 | 513 | 0.080 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2020 | 74 | 0.080 |
Why?
|
| Drug Resistance | 3 | 2012 | 112 | 0.080 |
Why?
|
| Somatoform Disorders | 1 | 2008 | 13 | 0.070 |
Why?
|
| Neurotransmitter Agents | 1 | 1988 | 42 | 0.070 |
Why?
|
| Incidence | 3 | 2015 | 1367 | 0.070 |
Why?
|
| Brain Chemistry | 2 | 1985 | 76 | 0.070 |
Why?
|
| Drug Evaluation | 2 | 2007 | 19 | 0.070 |
Why?
|
| Nucleoside-Phosphate Kinase | 3 | 1997 | 6 | 0.070 |
Why?
|
| Phobic Disorders | 3 | 2015 | 15 | 0.070 |
Why?
|
| Multiple Sclerosis | 1 | 2011 | 217 | 0.070 |
Why?
|
| Paroxetine | 2 | 1999 | 16 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 416 | 0.070 |
Why?
|
| Self Report | 3 | 2016 | 371 | 0.070 |
Why?
|
| Fatigue | 1 | 2008 | 112 | 0.070 |
Why?
|
| Monoamine Oxidase Inhibitors | 2 | 1998 | 10 | 0.070 |
Why?
|
| Peripartum Period | 2 | 2018 | 21 | 0.070 |
Why?
|
| Abortifacient Agents, Steroidal | 1 | 2006 | 2 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2019 | 2539 | 0.070 |
Why?
|
| 1-Naphthylamine | 2 | 1997 | 8 | 0.070 |
Why?
|
| Haloperidol | 1 | 2006 | 16 | 0.070 |
Why?
|
| Abortion, Induced | 1 | 2006 | 27 | 0.060 |
Why?
|
| Isocarboxazid | 1 | 1985 | 2 | 0.060 |
Why?
|
| Long-Term Care | 2 | 2021 | 177 | 0.060 |
Why?
|
| Obesity | 1 | 2014 | 1230 | 0.060 |
Why?
|
| Postnatal Care | 1 | 2006 | 43 | 0.060 |
Why?
|
| Algorithms | 2 | 2021 | 1003 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 3 | 1997 | 422 | 0.060 |
Why?
|
| Patient Selection | 2 | 2020 | 482 | 0.060 |
Why?
|
| Hallucinations | 2 | 2013 | 16 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1139 | 0.060 |
Why?
|
| Dizziness | 2 | 2019 | 18 | 0.060 |
Why?
|
| Psychomotor Agitation | 2 | 2016 | 19 | 0.050 |
Why?
|
| Neurokinin-1 Receptor Antagonists | 1 | 2004 | 23 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2025 | 497 | 0.050 |
Why?
|
| Chronic Disease | 3 | 2022 | 748 | 0.050 |
Why?
|
| Inositol | 1 | 2023 | 9 | 0.050 |
Why?
|
| Sleep | 3 | 1992 | 225 | 0.050 |
Why?
|
| Aspartic Acid | 1 | 2023 | 28 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 415 | 0.050 |
Why?
|
| Denmark | 2 | 2013 | 17 | 0.050 |
Why?
|
| Glutamine | 1 | 2023 | 46 | 0.050 |
Why?
|
| Drug Tolerance | 2 | 2004 | 33 | 0.050 |
Why?
|
| Hospital Records | 2 | 2000 | 8 | 0.050 |
Why?
|
| Monoamine Oxidase | 4 | 1987 | 8 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2003 | 138 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2021 | 3 | 0.050 |
Why?
|
| Psychotherapy | 1 | 1982 | 96 | 0.050 |
Why?
|
| Rage | 1 | 2001 | 1 | 0.050 |
Why?
|
| Propranolol | 3 | 1991 | 20 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1989 | 1589 | 0.050 |
Why?
|
| Pain | 1 | 2024 | 406 | 0.050 |
Why?
|
| Lithium Compounds | 1 | 2021 | 8 | 0.050 |
Why?
|
| Acute Disease | 1 | 2003 | 670 | 0.040 |
Why?
|
| Family | 1 | 2003 | 240 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2007 | 453 | 0.040 |
Why?
|
| Models, Biological | 2 | 2016 | 1180 | 0.040 |
Why?
|
| Principal Component Analysis | 2 | 2013 | 59 | 0.040 |
Why?
|
| Dibenzothiazepines | 1 | 2000 | 7 | 0.040 |
Why?
|
| Violence | 1 | 2001 | 155 | 0.040 |
Why?
|
| Blood Platelets | 3 | 1987 | 101 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 2019 | 24 | 0.040 |
Why?
|
| Allosteric Regulation | 1 | 2019 | 69 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 27 | 0.040 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2019 | 12 | 0.040 |
Why?
|
| Nifedipine | 2 | 1989 | 19 | 0.040 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2019 | 23 | 0.040 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2018 | 12 | 0.040 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2019 | 29 | 0.040 |
Why?
|
| Potassium Channels | 2 | 1996 | 58 | 0.040 |
Why?
|
| Nausea | 1 | 2019 | 112 | 0.040 |
Why?
|
| Ontario | 1 | 2018 | 44 | 0.040 |
Why?
|
| Hypertension | 3 | 2007 | 590 | 0.040 |
Why?
|
| MEDLINE | 1 | 1998 | 13 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 366 | 0.040 |
Why?
|
| Internal Capsule | 1 | 2018 | 11 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 505 | 0.040 |
Why?
|
| Corpus Callosum | 1 | 2018 | 42 | 0.040 |
Why?
|
| Nortriptyline | 1 | 1997 | 3 | 0.030 |
Why?
|
| Genotype | 1 | 2019 | 649 | 0.030 |
Why?
|
| Anhedonia | 1 | 2017 | 6 | 0.030 |
Why?
|
| Epinephrine | 3 | 1987 | 44 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2018 | 232 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2000 | 358 | 0.030 |
Why?
|
| Late Onset Disorders | 1 | 2017 | 3 | 0.030 |
Why?
|
| Basal Ganglia | 1 | 1997 | 34 | 0.030 |
Why?
|
| Cholesterol | 1 | 2018 | 259 | 0.030 |
Why?
|
| Blood Glucose | 2 | 2018 | 485 | 0.030 |
Why?
|
| Triglycerides | 1 | 2018 | 244 | 0.030 |
Why?
|
| Receptor Aggregation | 1 | 1996 | 5 | 0.030 |
Why?
|
| Verapamil | 1 | 1996 | 9 | 0.030 |
Why?
|
| Carbamazepine | 1 | 1996 | 11 | 0.030 |
Why?
|
| 20-alpha-Dihydroprogesterone | 1 | 2016 | 7 | 0.030 |
Why?
|
| Desoxycorticosterone | 1 | 2016 | 7 | 0.030 |
Why?
|
| Rats | 5 | 1997 | 1978 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2018 | 154 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2016 | 25 | 0.030 |
Why?
|
| Half-Life | 1 | 2016 | 77 | 0.030 |
Why?
|
| Trazodone | 1 | 1996 | 3 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1996 | 85 | 0.030 |
Why?
|
| Bupropion | 1 | 1996 | 8 | 0.030 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 1996 | 12 | 0.030 |
Why?
|
| Stroop Test | 1 | 2015 | 7 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 1996 | 166 | 0.030 |
Why?
|
| Mental Processes | 1 | 2015 | 18 | 0.030 |
Why?
|
| Men's Health | 1 | 2015 | 12 | 0.030 |
Why?
|
| Triazoles | 1 | 1996 | 56 | 0.030 |
Why?
|
| Phenotype | 1 | 2019 | 1191 | 0.030 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 1995 | 32 | 0.030 |
Why?
|
| Bulimia | 1 | 2015 | 17 | 0.030 |
Why?
|
| Progesterone | 1 | 2016 | 162 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 562 | 0.030 |
Why?
|
| Reaction Time | 1 | 2015 | 124 | 0.030 |
Why?
|
| Executive Function | 1 | 2015 | 64 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 277 | 0.030 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2014 | 3 | 0.030 |
Why?
|
| Feeding and Eating Disorders | 1 | 2015 | 49 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 375 | 0.030 |
Why?
|
| Snacks | 1 | 2014 | 5 | 0.030 |
Why?
|
| Health Surveys | 1 | 2015 | 312 | 0.030 |
Why?
|
| Lung Diseases | 1 | 1996 | 175 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 1995 | 193 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2015 | 203 | 0.030 |
Why?
|
| Amoxapine | 1 | 1993 | 1 | 0.030 |
Why?
|
| Metabolism | 1 | 2013 | 13 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2015 | 307 | 0.030 |
Why?
|
| Hospitals, Psychiatric | 1 | 2013 | 54 | 0.030 |
Why?
|
| Posture | 2 | 1991 | 127 | 0.030 |
Why?
|
| New England | 1 | 2014 | 272 | 0.030 |
Why?
|
| Amygdala | 1 | 2013 | 83 | 0.020 |
Why?
|
| Guilt | 1 | 1992 | 6 | 0.020 |
Why?
|
| Psychomotor Disorders | 1 | 1992 | 7 | 0.020 |
Why?
|
| Guanylate Kinases | 3 | 1997 | 8 | 0.020 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 775 | 0.020 |
Why?
|
| Disks Large Homolog 4 Protein | 3 | 1997 | 21 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 1997 | 705 | 0.020 |
Why?
|
| Prefrontal Cortex | 1 | 2013 | 118 | 0.020 |
Why?
|
| Syndrome | 1 | 2012 | 179 | 0.020 |
Why?
|
| Amphetamines | 1 | 1991 | 5 | 0.020 |
Why?
|
| Pulse | 1 | 1991 | 16 | 0.020 |
Why?
|
| Electroencephalography | 1 | 1992 | 147 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1992 | 140 | 0.020 |
Why?
|
| Consensus | 1 | 2012 | 225 | 0.020 |
Why?
|
| Proteins | 1 | 1997 | 750 | 0.020 |
Why?
|
| Hippocampus | 1 | 2013 | 267 | 0.020 |
Why?
|
| Retreatment | 1 | 2011 | 47 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2013 | 195 | 0.020 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 397 | 0.020 |
Why?
|
| Dopamine beta-Hydroxylase | 2 | 1987 | 13 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 1997 | 336 | 0.020 |
Why?
|
| Tyrosine 3-Monooxygenase | 2 | 1987 | 35 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 1989 | 31 | 0.020 |
Why?
|
| Registries | 1 | 2013 | 872 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 242 | 0.020 |
Why?
|
| Cerebral Ventricles | 1 | 1989 | 29 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 987 | 0.020 |
Why?
|
| Atrophy | 1 | 1989 | 83 | 0.020 |
Why?
|
| Amino Acid Sequence | 3 | 1997 | 1594 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 1997 | 1992 | 0.020 |
Why?
|
| Paranoid Disorders | 1 | 2008 | 2 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2015 | 2039 | 0.020 |
Why?
|
| Rats, Inbred Strains | 2 | 1985 | 150 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 725 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 768 | 0.020 |
Why?
|
| Canada | 1 | 2008 | 154 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2008 | 163 | 0.020 |
Why?
|
| Clinical Enzyme Tests | 1 | 1987 | 12 | 0.020 |
Why?
|
| Headache | 1 | 2007 | 58 | 0.020 |
Why?
|
| Vacuum Curettage | 1 | 2006 | 1 | 0.020 |
Why?
|
| Animals | 6 | 1997 | 20579 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 71 | 0.020 |
Why?
|
| SAP90-PSD95 Associated Proteins | 2 | 1997 | 2 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2007 | 89 | 0.020 |
Why?
|
| Personality Disorders | 1 | 2006 | 19 | 0.020 |
Why?
|
| Discs Large Homolog 1 Protein | 2 | 1996 | 3 | 0.020 |
Why?
|
| Outpatients | 1 | 2007 | 141 | 0.020 |
Why?
|
| International Cooperation | 1 | 2006 | 88 | 0.020 |
Why?
|
| Membrane Proteins | 3 | 1997 | 889 | 0.020 |
Why?
|
| Observer Variation | 1 | 2006 | 211 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 933 | 0.020 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 1985 | 5 | 0.020 |
Why?
|
| Self Concept | 1 | 2006 | 111 | 0.020 |
Why?
|
| Homovanillic Acid | 1 | 1985 | 6 | 0.020 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 1985 | 11 | 0.020 |
Why?
|
| Limbic System | 1 | 1985 | 27 | 0.020 |
Why?
|
| Cats | 1 | 1985 | 86 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 1984 | 24 | 0.010 |
Why?
|
| Nucleus Accumbens | 1 | 1985 | 43 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1984 | 63 | 0.010 |
Why?
|
| Hypothalamus | 1 | 1985 | 132 | 0.010 |
Why?
|
| Corpus Striatum | 1 | 1985 | 96 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 2 | 1996 | 198 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2008 | 429 | 0.010 |
Why?
|
| Prolactin | 1 | 1984 | 40 | 0.010 |
Why?
|
| Social Support | 1 | 2006 | 370 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 1996 | 427 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1982 | 11 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1984 | 173 | 0.010 |
Why?
|
| Trail Making Test | 1 | 2000 | 5 | 0.010 |
Why?
|
| Wechsler Scales | 1 | 2000 | 15 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 2000 | 46 | 0.010 |
Why?
|
| Schizophrenia, Paranoid | 1 | 2000 | 2 | 0.010 |
Why?
|
| Quetiapine Fumarate | 1 | 2000 | 13 | 0.010 |
Why?
|
| Frontal Lobe | 1 | 2000 | 65 | 0.010 |
Why?
|
| Infant Mortality | 1 | 1980 | 20 | 0.010 |
Why?
|
| Schizophrenic Psychology | 1 | 2000 | 68 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 1984 | 536 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2000 | 137 | 0.010 |
Why?
|
| Random Allocation | 2 | 1989 | 197 | 0.010 |
Why?
|
| Age of Onset | 1 | 1998 | 175 | 0.010 |
Why?
|
| COS Cells | 1 | 1997 | 174 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 1996 | 68 | 0.010 |
Why?
|
| Ion Channels | 1 | 1997 | 90 | 0.010 |
Why?
|
| Kv1.4 Potassium Channel | 1 | 1995 | 1 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1995 | 84 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1996 | 293 | 0.010 |
Why?
|
| Rabbits | 1 | 1996 | 332 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 1997 | 178 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 1996 | 1341 | 0.010 |
Why?
|
| Birth Weight | 1 | 1996 | 85 | 0.010 |
Why?
|
| Synapses | 1 | 1997 | 185 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1995 | 383 | 0.010 |
Why?
|
| Binding Sites | 1 | 1997 | 900 | 0.010 |
Why?
|
| Base Sequence | 1 | 1997 | 1333 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1996 | 890 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1995 | 495 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1995 | 493 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 1996 | 295 | 0.010 |
Why?
|
| Sleep, REM | 1 | 1992 | 9 | 0.010 |
Why?
|
| Sleep Stages | 1 | 1992 | 16 | 0.010 |
Why?
|
| Cell Line | 1 | 1995 | 2038 | 0.010 |
Why?
|
| Sleep Wake Disorders | 1 | 1992 | 69 | 0.010 |
Why?
|
| Protein Binding | 1 | 1995 | 1601 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1995 | 564 | 0.010 |
Why?
|
| Infusion Pumps | 1 | 1989 | 7 | 0.010 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 1989 | 35 | 0.000 |
Why?
|
| Circadian Rhythm | 1 | 1992 | 381 | 0.000 |
Why?
|
| Tablets | 1 | 1987 | 16 | 0.000 |
Why?
|
| Intestinal Absorption | 1 | 1987 | 31 | 0.000 |
Why?
|
| Diuretics | 1 | 1987 | 63 | 0.000 |
Why?
|
| Multicenter Studies as Topic | 1 | 1987 | 137 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1984 | 104 | 0.000 |
Why?
|
| Biogenic Amines | 1 | 1984 | 2 | 0.000 |
Why?
|
| Diabetes Complications | 1 | 1984 | 106 | 0.000 |
Why?
|
| Hypoglycemia | 1 | 1984 | 67 | 0.000 |
Why?
|
| Synaptic Transmission | 1 | 1985 | 150 | 0.000 |
Why?
|
| Alcoholism | 1 | 1986 | 319 | 0.000 |
Why?
|
| Paris | 1 | 1980 | 5 | 0.000 |
Why?
|
| Fetal Diseases | 1 | 1980 | 21 | 0.000 |
Why?
|
| Congenital Abnormalities | 1 | 1980 | 26 | 0.000 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1980 | 31 | 0.000 |
Why?
|
| Hospitals, Pediatric | 1 | 1980 | 52 | 0.000 |
Why?
|
| Metabolic Diseases | 1 | 1980 | 57 | 0.000 |
Why?
|
| Communicable Diseases | 1 | 1980 | 88 | 0.000 |
Why?
|
| Infant | 1 | 1980 | 1602 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1980 | 1937 | 0.000 |
Why?
|
| Child | 1 | 1980 | 4444 | 0.000 |
Why?
|